Stay updated on Cabozantinib in Salivary Gland Cancer: Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in Salivary Gland Cancer: Clinical Trial page.

Latest updates to the Cabozantinib in Salivary Gland Cancer: Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page now displays the study record for a phase 2 cabozantinib trial in advanced salivary gland cancer, including its terminated status, eligibility criteria, study design, outcomes, and related publications.SummaryDifference51%

- Check14 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces an NIH website transition and says that both “Artificial Intelligence” and “Super Intelligence” terminology may appear during the transition.SummaryDifference1%

- Check28 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2; the page otherwise remains a 403 error screen.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer site revision changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with a simple error screen and minimal navigation.SummaryDifference19%

Stay in the know with updates to Cabozantinib in Salivary Gland Cancer: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in Salivary Gland Cancer: Clinical Trial page.